TSE
Every company in the roster listed on TSE.
Every company in the roster listed on TSE.
27 of 27 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
AnGes4563 · TSE | 1 asset: 1 Ph 3 | Beperminogene perplasmid (HGF plasmid)Phase 3 · Atherosclerotic Cardiovascular Disease | None on record | — | $12MDec 2025 | Ended Feb 2026 | $24M |
Asahi Kasei Corporation3407 · TSE | 2 assets: 1 approved, 1 Ph 2 | SetanaxibPhase 2 · Primary Biliary CholangitisPartial signal | Mar 2027Budesonide (targeted-release) · Approved | — | — | — | — |
Astellas Pharma4503 · TSE | 15 assets: 4 approved, 4 Ph 3, 4 Ph 2, 3 Ph 1 | RoxadustatPhase 3 · Chronic Kidney DiseaseReliable signal | 30 Dec 2026ASP546C · Phase 1/2 | — | $1.8BMar 2026 | — | $2.1B |
BrightPath Biotherapeutics Co., Ltd.4594 · TSE | 1 asset: 1 Ph 1 | BP2202Phase 1 · Multiple Myeloma | 31 Dec 2027BP2202 · Phase 1 | — | $14MMar 2026 | ~6.3 qtrs | — |
Chugai Pharma4519 · TSE | 14 assets: 10 approved, 2 Ph 3, 1 Ph 2, 1 Ph 1 | enicepatidePhase 3 · ObesityReliable signal | 30 Nov 2026Atezolizumab · Phase 3 | — | — | — | $1.3B |
Daiichi Sankyo4568 · TSE | 21 assets: 10 approved, 6 Ph 3, 4 Ph 2, 1 Ph 1 | Denosumab (Xgeva)Phase 3 · Multiple MyelomaReliable signal | 17 Dec 2026bevacizumab-awwb · Phase 1 | — | $3.1BMar 2026 | — | $3.0B |
Eisai4523 · TSE | 18 assets: 10 approved, 4 Ph 3, 4 Ph 2 | SerplulimabPhase 3 · Non-Small Cell Lung CancerReliable signal | 29 Nov 2026Rimegepant (Nurtec ODT) · Phase 3 | — | $1.5BMar 2026 | — | $1.0B |
Fuji Pharma Co., Ltd.4554.T · TSE | 1 asset: 1 Ph 3 | ColestilanPhase 3 · Chronic Kidney DiseasePartial signal | None on record | — | — | — | — |
Heartseed219A · TSE | 1 asset: 1 Ph 2 | HS-001Phase 1/2 · Heart Failure | None on record | — | $40MMar 2026 | 10+ years | — |
JCR Pharmaceuticals4552 · TSE | 3 assets: 2 approved, 1 Ph 3 | JR-131Phase 3 · Chronic Kidney DiseasePartial signal | Dec 2026Givinostat · Phase 2 | — | — | — | — |
Kaken Pharmaceutical4521 · TSE | 2 assets: 1 approved, 1 Ph 3 | EnvudeucitinibPhase 3 · PsoriasisReliable signal | 1 Dec 2027Envudeucitinib · Phase 2 | — | — | — | — |
Kissei Pharmaceutical4547 · TSE | 7 assets: 3 approved, 3 Ph 3, 1 Ph 2 | OmarigliptinPhase 3Reliable signal | 30 Apr 2027Olutasidenib · Approved | — | $330MMar 2026 | — | $148M |
Kureha Corporation4023 · TSE | 1 asset: 1 Ph 3 | AST-120Phase 3 · Chronic Kidney DiseasePartial signal | None on record | — | — | — | — |
Kyowa Kirin4151 · TSE | 9 assets: 6 approved, 3 Ph 1 | KK2269Phase 1 · Non-Small Cell Lung Cancer | Dec 2026Ziftomenib · Phase 1 | — | $1.4BDec 2025 | — | $676M |
Nippon Kayaku4272 · TSE | 2 assets: 1 approved, 1 Ph 2 | DarinaparsinPhase 2 · Peripheral T-Cell LymphomaWeak signal | 2 Feb 2027Taletrectinib · Phase 1 | — | — | — | — |
Nippon Shinyaku4516 · TSE | 6 assets: 4 approved, 2 Ph 3 | Clemidsogene lanparvovecPhase 3 · Mucopolysaccharidosis Type II | 30 Apr 2027Ferric derisomaltose · Phase 3 | — | — | — | — |
Nxera Pharma4565 · TSE | 1 asset: 1 Ph 3 | DireclidinePhase 3 · SchizophreniaPartial signal | Oct 2027Direclidine · Phase 3 | — | — | — | — |
Ono Pharmaceutical4528 · TSE | 16 assets: 11 approved, 1 Ph 3, 2 Ph 2, 2 Ph 1 | ONO-4578Phase 3 · Gastric CancerReliable signal | 10 Dec 2026Dapagliflozin · Phase 2 | — | $1.5BMar 2026 | — | $969M |
Otsuka Holdings4578 · TSE | 23 assets: 15 approved, 4 Ph 3, 2 Ph 2, 2 Ph 1 | UlefnersenPhase 3 · Amyotrophic Lateral SclerosisReliable signal | Dec 2026Donidalorsen · Phase 3 | — | $3.4BMar 2026 | — | ~$2.1B |
Rohto Pharmaceutical4527 · TSE | 1 asset: 1 Ph 2 | ADR-002KPhase 2 · Heart Failure | 30 Sep 2028ADR-002K · Phase 2 | — | $522MMar 2026 | — | $91M |
Santen Pharmaceutical Co., Ltd.4536 · TSE | 1 asset: 1 Ph 3 | RC28-EPhase 3 · Age-Related Macular DegenerationPartial signal | 1 Dec 2028RC28-E · Phase 3 | — | — | — | — |
Shin Nippon Biomedical Laboratories2395 · TSE | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Shionogi4507 · TSE | 7 assets: 5 approved, 2 Ph 3 | EnarodustatPhase 3 · Chronic Kidney DiseaseReliable signal | 25 Jan 2027Rosuvastatin · Phase 1 | — | $4.5BMar 2026 | — | $810M |
Solasia Pharma K.K.4597 · TSE | 1 asset: 1 Ph 2 | DarinaparsinPhase 2 · Peripheral T-Cell LymphomaWeak signal | None on record | — | — | — | — |
Sumitomo Pharma4506 · TSE | 7 assets: 3 approved, 1 Ph 3, 3 Ph 2 | VildagliptinPhase 3 · Type 2 DiabetesPartial signal | 30 Jun 2027Enzomenib · Phase 1/2 | — | — | — | $289M |
Teijin3401 · TSE | 5 assets: 3 approved, 1 Ph 3, 1 Ph 2 | TrelagliptinPhase 3 · Type 2 DiabetesPartial signal | Aug 2027palopegteriparatide · Phase 3 | — | — | — | — |
Zeria Pharmaceutical Co., Ltd.4559 · TSE | 1 asset: 1 Ph 3 | PatiromerPhase 3 · Chronic Kidney DiseasePartial signal | 1 Dec 2029Patiromer · Phase 2 | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.